They noted that key studies of the new treatment-
a drug called nusinersen(marketed as Spinraza by Biogen of Cambridge, Massachusetts)-
are still ongoing, involve small numbers of children, and are unpublished.
But this week, Biogen and Esai, the drug companies behind aducanumab, ended clinical
trials involving thousands of patients early, stating that the“trials were unlikely to meet their primary endpoint upon completion”.